Fabry Disease Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

 Breaking News
  • No posts were found

Fabry Disease Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

May 10
20:01 2023
Fabry Disease Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP

As per DelveInsight’s assessment, globally, about 18+ key pharma and biotech companies are working on 18+ pipeline drugs in the Fabry Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Fabry Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Fabry Disease Market. 

The Fabry Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Fabry Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Fabry Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Fabry Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Fabry Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy


Latest Key Developments in the Fabry Disease Therapeutics Market

On May 10, 2023, Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. (NYSE American:PLX) announced that the U.S. Food and Drug Administration (FDA) has approved ELFABRIO (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Fabry Disease Therapeutic Segment @

Fabry Disease Therapeutics Landscape

There are approx. 18+ key companies developing therapies for Fabry Disease. Currently, Protalix Biotherapeutics is leading the therapeutics market with its Fabry Disease drug candidates in the most advanced stage of clinical development.

The Leading Players in the Fabry Disease Therapeutics Market Include:

  • Idorsia Pharmaceuticals

  • Protalix

  • Sanofi Genzyme

  • Sangamo Therapeutics

  • 4D Molecular Therapeutics

  • Resverlogix Corp


  • Freeline Therapeutics

  • Ozmosis Research Inc.

  • CellGenTech, Inc.

  • uniQure

  • Codexis

  • Canbridge

  • Eleva GmbH

  • MP6 therapeutics

  • Amicus therapeutics

  • Sigilon Therapeutics

And Many Others

Fabry Disease Emerging and Marketed Drugs Covered in the Report Include:

  • 4D 310: 4D Molecular Therapeutics

  • Fabrazyme (agalsidase beta): Sanofi-Genzyme

  • Pegunigalsidase Alfa: Protalix Biotherapeutics

  • PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics

  • Replagal (agalsidase alfa): Shire (now a part of Takeda)

  • Venglustat: Sanofi Genzyme

  • Replagal: Shire/Takeda

  • Galafold: Amicus Therapeutics

  • PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics

  • Venglustat: Sanofi Genzyme

  • ST-920: Sangamo Therapeutics

  • FLT190: Freeline Therapeutics

  • Lucerastat: Idorsia Pharmaceuticals


And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Fabry Disease Current Treatment Patterns

4. Fabry Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Fabry Disease Late Stage Products (Phase-III)

7. Fabry Disease Mid-Stage Products (Phase-II)

8. Fabry Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Fabry Disease Discontinued Products

13. Fabry Disease Product Profiles

14. Key Companies in the Fabry Disease Market

15. Key Products in the Fabry Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Fabry Disease Unmet Needs

18. Fabry Disease Future Perspectives

19. Fabry Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States